Patents by Inventor Jeanne Baker

Jeanne Baker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180223322
    Abstract: The present disclosure provides activated formylglycine-generating enzymes (FGE), methods of producing activated FGE, and their use in methods of producing a protein comprising a formylglycine (FGly) residue. The methods of producing activated FGE, as well as methods of use of activated FGE in producing FGly-containing proteins, include both cell-based and cell-free methods. Compositions and kits that find use, e.g., in practicing the methods of the present disclosure are also provided.
    Type: Application
    Filed: January 4, 2018
    Publication date: August 9, 2018
    Inventors: David Rabuka, Gregory W. deHart, Patrick Holder, Jeanne Baker
  • Patent number: 9951367
    Abstract: The present disclosure provides activated formylglycine-generating enzymes (FGE), methods of producing activated FGE, and their use in methods of producing a protein comprising a formylglycine (FGly) residue. The methods of producing activated FGE, as well as methods of use of activated FGE in producing FGly-containing proteins, include both cell-based and cell-free methods. Compositions and kits that find use, e.g., in practicing the methods of the present disclosure are also provided.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: April 24, 2018
    Assignee: R.P. Scherer Technologies, LLC
    Inventors: David Rabuka, Gregory W. deHart, Patrick Holder, Jeanne Baker
  • Publication number: 20180105602
    Abstract: Described herein are anti-MCAM antibodies and antigen binding fragments thereof that are capable of inhibiting the interaction between MCAM and its ligand, a protein comprising a laminin ?-4 chain. These anti-MCAM antibodies and antigen binding fragments thereof may be useful for, for example, treating inflammatory conditions characterized by the infiltration of MCAM-expressing cells into a site of inflammation in the body.
    Type: Application
    Filed: October 5, 2017
    Publication date: April 19, 2018
    Inventors: Kenneth Flanagan, Jeanne Baker, Theodore A. Yednock
  • Publication number: 20170145109
    Abstract: Described herein are anti-MCAM antibodies and antigen binding fragments thereof that are capable of inhibiting the interaction between MCAM and its ligand, a protein comprising a laminin ?-4 chain. These anti-MCAM antibodies and antigen binding fragments thereof may be useful for, for example, treating inflammatory conditions characterized by the infiltration of MCAM-expressing cells into a site of inflammation in the body.
    Type: Application
    Filed: July 28, 2016
    Publication date: May 25, 2017
    Inventors: Kenneth Flanagan, Jeanne Baker, Theodore A. Yednock
  • Publication number: 20170037144
    Abstract: Described herein are anti-MCAM antibodies and antigen binding fragments thereof that are capable of inhibiting the interaction between MCAM and its ligand, a protein comprising a laminin ?-4 chain. These anti-MCAM antibodies and antigen binding fragments thereof may be useful for, for example, treating inflammatory conditions characterized by the infiltration of MCAM-expressing cells into a site of inflammation in the body.
    Type: Application
    Filed: July 28, 2016
    Publication date: February 9, 2017
    Inventors: Kenneth Flanagan, Jeanne Baker, Theodore A. Yednock
  • Patent number: 9447190
    Abstract: Described herein are anti-MCAM antibodies and antigen binding fragments thereof that are capable of inhibiting the interaction between MCAM and its ligand, a protein comprising a laminin ?-4 chain. These anti-MCAM antibodies and antigen binding fragments thereof may be useful for, for example, treating inflammatory conditions characterized by the infiltration of MCAM-expressing cells into a site of inflammation in the body.
    Type: Grant
    Filed: September 9, 2013
    Date of Patent: September 20, 2016
    Assignee: PROTHENA BIOSCIENCES LIMITED
    Inventors: Kenneth Flanagan, Jeanne Baker, Theodore A. Yednock
  • Publication number: 20160230205
    Abstract: The present disclosure provides activated formylglycine-generating enzymes (FGE), methods of producing activated FGE, and their use in methods of producing a protein comprising a formylglycine (FGly) residue. The methods of producing activated FGE, as well as methods of use of activated FGE in producing FGly-containing proteins, include both cell-based and cell-free methods. Compositions and kits that find use, e.g., in practicing the methods of the present disclosure are also provided.
    Type: Application
    Filed: December 18, 2015
    Publication date: August 11, 2016
    Inventors: David Rabuka, Gregory W. deHart, Patrick Holder, Jeanne Baker
  • Publication number: 20150239980
    Abstract: Described herein are anti-MCAM antibodies and antigen binding fragments thereof that are capable of inhibiting the interaction between MCAM and its ligand, a protein comprising a laminin ?-4 chain. These anti-MCAM antibodies and antigen binding fragments thereof may be useful for, for example, treating inflammatory conditions characterized by the infiltration of MCAM-expressing cells into a site of inflammation in the body.
    Type: Application
    Filed: September 9, 2013
    Publication date: August 27, 2015
    Inventors: Kenneth Flanagan, Jeanne Baker, Theodore A. Yednock
  • Publication number: 20140314744
    Abstract: Described herein are MCAM antagonists, including MCAM antagonist antibodies capable of inhibiting the interaction between MCAM and it ligand, a laminin ?4 chain, e.g., an ?4 chain of laminin 411. These MCAM antagonists, e.g., anti-MCAM antibodies, may be useful to treat neuroinflammatory conditions, for example, multiple sclerosis and Parkinson's disease, by inhibiting the infiltration of MCAM-expressing cells into the central nervous system (CNS), e.g., extravasation of TH17 cells into the CNS.
    Type: Application
    Filed: June 6, 2012
    Publication date: October 23, 2014
    Applicant: Neotope Biosciences Limited
    Inventors: Kenneth Flanagan, Jennifer Johnston, Theodore Yednock, Jeanne Baker
  • Publication number: 20140227292
    Abstract: Described herein are anti-MCAM antibodies and antigen binding fragments thereof that are capable of inhibiting the interaction between MCAM and its ligand, a protein comprising a laminin ?-4 chain. These anti-MCAM antibodies and antigen binding fragments thereof may be useful for, for example, treating inflammatory conditions characterized by the infiltration of MCAM-expressing cells into a site of inflammation in the body.
    Type: Application
    Filed: September 9, 2013
    Publication date: August 14, 2014
    Inventors: Kenneth Flanagan, Jeanne Baker, Theodore A. Yednock
  • Publication number: 20050033677
    Abstract: A system and method for processing electronic claims (“e-claims”) for employee benefits program is disclosed. A debit card transaction for an e-claim is automatically detected. By auditing the e-claim and receipts associated with the e-claim, a determination is made as to whether the transaction is an eligible claim that can be reimbursed. If the e-claim is not eligible for payment, the system and method of the present invention automatically tracks and sends notification to the participant to pay back the money. If the participant does not pay back after a number of requests, his debit card is automatically deactivated. Further, as soon as the e-claim is detected, the system and method automatically makes a request to the participant to send in the receipt associated with the e-claim for auditing if the receipt was not received previously. If the receipt is not received within a predetermined amount of time, the participant's debit card for making e-claims is automatically deactivated.
    Type: Application
    Filed: September 14, 2004
    Publication date: February 10, 2005
    Inventors: Robin Birdsong, Jeanne Baker